Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

262.03 5.90 −2.20%
Market cap
$40.5B
P/E
48.4×
Fwd P/E
34.7×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
32.38% 33.82% 33.36% 31.16%

+8 more TTM periods

Piotroski F-Score
6 6 8 8
ROA
12.95% 13.39% 13.13% 11.52%
ROIC
17.46% 17.69% 19.55% 23.22%
Return on Tangible Assets
41.23% 44.27% 34.51% 44.37%
Average Days of Receivables
62.07 61.32 71.77 62.05
Free Cash Flow per Share
6.17 6.37 6.01 6.54
Free Cash Flow
931.00 974.00 931.00 1,000.00
Other line items

Show all line items

Columns are period end dates